Business
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric officesPrivate convertible notes financing will supp
About this update from Pelthos Therapeutics Inc.
[{"type":"image","alt":"Pelthos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pelthos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yWW833l91CiuD7s17uRPhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355","width":300,"height":179}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting children","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Impetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric offices","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Private convertible notes financing will support the acquisition and re-launch of Xepi, accelerate the commercialization of ZELSUVMI for molluscum contagiosum, and for general working capital purposes","length":200,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":655,"olType":false},{"type":"text","content":"DURHAM, N.C., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired the U.S. commercialization rights to Xepi® (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A. (the “Acquisition”). Xepi is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older.","length":613,"tagName":"p"},{"type":"text","content":"The Company has also closed on an $18 million private convertible notes financing (the “Notes”) with existing investors, including Ligand Pharmaceutic...